Clinical trials: Obesity or Overweight
Obesity
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy"…
- Trial name
- STEP Young (NCT05726227)
- Testing
- Semaglutide
- Where
- 56 sites in United States, Austria and 8 more
- Volunteers
- 212 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
The aim of this study is to find out how NNC0174-0833 taken with semaglutide works in people who are overweight or obese. Both study medicines have been investigated on their own.
- Trial name
- NCT03600480
- Testing
- NNC0174-0833, Semaglutide
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Novo Nordisk A/S
Overweight, Type 2 Diabetes
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
The main purpose of this study is to investigate efficacy and safety of three doses of petrelintide versus placebo in participants with overweight or obesity and type 2 diabetes.
- Conditions
- Overweight, Type 2 Diabetes, Obesity
- Trial name
- NCT06926842
- Testing
- Petrelintide
- Where
- 48 sites in United States
- Volunteers
- 221 people
- Sponsor
- Zealand Pharma
Obesity
A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study was to evaluate the safety and tolerability of RGT001-075 in healthy participants with obesity
- Trial name
- NCT06277934
- Testing
- RGT001-075
- Where
- 10 sites in United States
- Volunteers
- 73 people
- Sponsor
- Regor Pharmaceuticals Inc.
Obesity or Overweight
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or…
- Trial name
- ZUPREME-3 (NCT07843498)
- Testing
- Petrelintide
- Where
- 8 sites in United States
- Volunteers
- 3,900 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2, Obesity
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
This trial will evaluate use of BI 10773 as add-on to insulin regimen alone or with metformin in patients with typr 2 diabetes. Both lowering glucose and HbA1c and reducing the use of insulin in this population would provide…
- Trial name
- NCT01306214
- Testing
- BI 10773
- Where
- 103 sites in United States, Belgium and 12 more
- Volunteers
- 566 people
- Sponsor
- Boehringer Ingelheim
Obesity or Overweight
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with…
- Trial name
- Enith1 (NCT07351045)
- Testing
- Enicepatide
- Where
- 209 sites in United States, Argentina and 19 more
- Volunteers
- 2,000 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus (T2DM), Overweight or Obese
A Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
The purpose of this study is to assess how fast BGM0504 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT06929156
- Testing
- BGM0504
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Obesity/Overweight in Adult
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate…
- Trial name
- NCT07150975
- Testing
- GZR18, Semaglutide(Wegovy® )
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity.
- Trial name
- NCT06075667
- Testing
- Tirzepatide
- Where
- 33 sites in United States, Canada and 4 more
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Obesity
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses
1. Study Objective i) To evaluate the safety, tolerability and pharmacokinetic/pharmacodynamic characteristics of HSG4112 after single and multiple oral administration of high doses in healthy subjects.
- Trial name
- NCT05310032
- Testing
- HSG4112
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Glaceum
Overweight or Obesity
Probiotic Influence on Obesity-Related Lipidemia
This study aims to investigate the effects of Bifidobacterium breve BBr60 on key health indicators in overweight and obese adults.
- Trial name
- NCT06305650
- Testing
- Probiotic
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Obesity
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
- Trial name
- MARITIME-1 (NCT06858839)
- Testing
- Maridebart Cafraglutide
- Where
- 243 sites in United States, Argentina and 15 more
- Volunteers
- 3,853 people
- Sponsor
- Amgen
Overweight, Obesity
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
The main purpose of this study is to learn about the safety and tolerability of LY3502970 when given to Chinese participants with obesity or overweight with weight-related comorbidities.
- Trial name
- NCT06023095
- Testing
- LY3502970
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Obesity
Registry Observing EndoBarrier® Treatment Outcomes in Subjects With Type 2 Diabetes and/or Obesity
The purpose of the registry was to observe the safety and effectiveness outcomes for subjects treated with the EndoBarrier in the post market setting where the product had Conformité Européene (CE mark) regulatory approval and in…
- Trial name
- NCT03072901
- Testing
- EndoBarrier Gastrointestinal Liner
- Volunteers
- 244 people
- Sponsor
- Morphic Medical Inc.
Obesity, Overweight
Medications With or Without WeightWatchers
The study compares the effectiveness of adults living with overweight or obesity taking weight management medications alone vs taking them with behavioral and lifestyle support.
- Trial name
- Meds WOW-WW (NCT06470659)
- Testing
- WW Clinic
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Michelle Cardel, PhD, MS, RD
Overweight, Obesity
A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease
The purpose of this study is to evaluate the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), as a therapy to reduce the risk of…
- Conditions
- Overweight, Obesity, Cardiovascular Disease
- Trial name
- Enith-MACE (NCT07918846)
- Testing
- Enicepatide
- Volunteers
- 8,200 people
- Sponsor
- Hoffmann-La Roche
Overweight, Obesity
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D).
- Conditions
- Overweight, Obesity, Type 2 Diabetes
- Trial name
- NCT07855133
- Testing
- Semaglutide, Zenagamtide
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes.
- Trial name
- NCT06901349
- Testing
- Bimagrumab, Tirzepatide
- Where
- 50 sites in United States, Argentina and 3 more
- Sponsor
- Eli Lilly and Company
Metabolic Syndrome, Obesity
Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers
The purpose of this study is to investigate the safety and tolerability of MB12066 after a single or multiple oral dose and to investigate the pharmacokinetic characteristics of MB12066 after a single or multiple oral dose.
- Trial name
- NCT01444677
- Testing
- MB12066
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Yungjin Pharm. Co., Ltd.